NCT04878731View on ClinicalTrials.gov

Study to Evaluate Safety and Tolerability of a Single Dose of PF-06741086 in Chinese Adult Participants With Severe Hemophilia

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 16, 2021

Primary Completion Date

August 10, 2021

Study Completion Date

August 10, 2021

Conditions
Severe Hemophilia
Interventions
BIOLOGICAL

PF-06741086

single dose SC injection of 300 mg PF-06741086

Trial Locations (1)

300020

Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04878731 - Study to Evaluate Safety and Tolerability of a Single Dose of PF-06741086 in Chinese Adult Participants With Severe Hemophilia | Biotech Hunter | Biotech Hunter